Global Hyperspectral Imaging System Market Outlook, Key Financials, Segmental Revenue And Geographical Revenue Till 2025

Global Hyperspectral Imaging System Market held a value of USD 10,700 Million in 2018, at a CAGR of 17.4% during the assessment period of 2019 to 2025.

Hyperspectral Imaging System Market Synopsis

Hyperspectral Imaging Systems (HIS) are also known as imaging spectroscopy. It was originated from remote sensing and has various applications in surveillance, remote sensing, machine vision/optical, and medical diagnostics. It can acquire 2D images across a wide range of the electromagnetic spectrum. Increasing applications for research in life sciences and the medical diagnostics sector in the past few years are responsible for a surge in demand for hyperspectral imaging systems. The key players involved in this market are actively focusing upon building partnerships, collaborations, and joint ventures with hospitals and ambulatory centers to strengthen their position in the market. Moreover, there is an increasing growth in various chronic diseases, which pushes the need for efficient hyperspectral imaging systems in the developing as well as underdeveloped regions.

Hyperspectral Imaging System Market Influencer

Rising funding and investments for the development of hyperspectral medical imaging systems are likely to provide favorable conditions for the growth of the hyperspectral medical imaging system market during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8741

Hyperspectral Imaging System Market Drivers

• The growing industrial applications of hyperspectral imaging is anticipated to drive the growth of the market during the forecast period. It has various applications in food & agriculture, healthcare, defense, mining, and metrology industries.

• Innovative and easy to use product launched in recent years

• Rising spending on scientific research and aerospace industry

• The growing prevalence of cancer and increasing awareness of innovative diagnostics methods is providing favorable conditions for the growth of the market during the forecast period. According to the US Department of Health and Human Services, 1,735,350 new cases of cancer were detected in the US in 2018. It is expected to accelerate the demand for hyperspectral imaging systems during the study period

• High investment in research and development for the development of efficient imaging solutions

Market Restraints

• High costs associated with HIS are likely to hamper the market growth

• Data storage-related issues associated with HIS

Hyperspectral Imaging System Market Segmentation

By Product

• Visible/Near-Infrared (VNIR): These systems create a false-color composite image made using near-infrared, green, and blue wavelengths. They are used in healthcare and agriculture sectors. VNIR segment is estimated to hold the largest market share during the forecast period due to the ease in operating and high efficiency of VNIR products

• Mid-Wave Infrared (MWIR): Mid-Wave Infrared (MWIR) systems operate in wavelengths ranging from 3µm to 5µm (3000nm to 5000nm). This segment is anticipated to be the fastest-growing segment owing to the rising adoption of MWIR systems in detecting volcanic vents, industrial gas leaks, or biomass burning events.

• Short-Wave Infrared (SWIR): It operates in wavelengths between 1,050 and 2,500 nm and used in inspection, sorting, and quality control. It has various applications including surveillance and remote sensing.

• Long-Wave Infrared (LWIR): Long-Wave Infrared (LWIR) systems are used in the detection of minerals such as quartz, adularia, albite, kaolinite, orthoclase, Na- and Ca-montmorillonite, calcite, opal, chalcedony, gypsum, alunite, jarosite, and other sulfates.

By Technology

• Pushbroom: These devices are made up of digital micromirror devices (DMD), CMOS image sensors. It is also called a line scan. This segment is estimated to hold maximum market share during the forecast period. The growth of this segment is attributed to the growing popularity of push broom systems in computer vision, remote sensing, biomedicine, surveillance, precision agriculture, environmental studies, forensics, nanoparticle research, food science, mining, forestry, etc.

• Snapshot: Snapshot hyperspectral imagers are fast as compare to other systems. This segment is expected to register the fastest CAGR during the forecast period.

• Others: Others include whiskbroom, tunable filter, and other technologies.

By Application

• Surveillance: The majority of the hyperspectral imaging systems are used for defense and surveillance. Additionally, it can detect satellites, high-altitude reconnaissance aircraft, medium-altitude commercial aircraft, and drones. The market growth of the segment is majorly attributed to the increasing adoption of innovative technologies in the defense sector, along with the rising applications of unmanned aerial vehicles for surveillance purposes.

• Medical Diagnostics: Medical diagnostics segment is anticipated to be the fastest-growing segment owing to the increasing applications of the hyperspectral imaging system in healthcare, such as the detection of the chemical composition of human tissues. Additionally, it has potential applications in non-invasive diagnosis.

• Remote Sensing: Remote sensing is likely to hold significant market share in the global hyperspectral imaging system market. It is also known as imaging spectroscopy. It is used for the detection and identification of minerals, terrestrial vegetation, and human-made materials and backgrounds.

• Machine Vision/Optical: Various hyperspectral imaging systems are used for machine vision/optical purposes.

By Region

• Americas: Americas is estimated to be the largest regional market owing to the presence of prominent players in the major countries in America. Major market players such as Headwall Photonics, Inc., Resonon, Inc., Corning Incorporated, Applied Spectral Imaging, and Surface Optics Corporation have a significant presence in the Americas. The region is anticipated to dominate the global hyperspectral imaging system market owing to the well-established healthcare sector and rising healthcare spending in the region. According to the Committee for a Responsible Federal Budget, in 2017, the US has spent more than USD 3.5 trillion on healthcare-related expenses.

• Europe: The European region holds the second largest share as there is increasing support from regulatory authorities to control cancer. Moreover, the rising expenses on defense and surge in demand for innovative and easy to use hyperspectral imaging systems have led to an increase in demand for hyperspectral imaging systems in the region.

• Asia-Pacific: The Asia-Pacific region is anticipated to be the fastest-growing region in the global hyperspectral imaging system market. This region is witnessing a surge due to the increasing mining activities, and growing biotechnology and agriculture sector in developing countries such as India. According to the India Brand Equity Foundation, the Indian biotechnology sector is likely to reach around USD 12 billion in the year 2018. The growing biotechnology sector is likely to provide favorable conditions and anticipated to drive growth in the market.

• Middle East & Africa: The smallest market due to limited healthcare infrastructure and limited exposure to innovative solutions.

Key Players

• Headwall Photonics, Inc.
• Specim, Spectral Imaging Ltd.
• Norsk Elektro Optikk as (NEO)
• Resonon, Inc.
• Corning Incorporated
• Telops
• Applied Spectral Imaging
• Bayspec, Inc.
• Surface Optics Corporation
• Chemimage Corporation
• Cubert GmbH
• Raytheon
• Galileo Group, Inc.
• Hypermed Imaging, Inc.
• Inno-Spec
• Camlin Group Ltd.
• IMEC
• XIMEA GmbH
• OthersTop of Form

Bottom of Form

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/hyperspectral-imaging-system-market-8741

Global 4D Printing in Healthcare Market Growth Factors, Types And Application By Regional Analysis 2025

Market Overview

Global 4D Printing in Healthcare Market is expected to register a CAGR of 29.4% during the forecast period from 2019 to 2025 and expected to reach USD 30.4 Million by 2025.

In the past decade, there has been increasing use of 3D printing in the field of healthcare. The introduction of 4D printing and its shape-changing material property in the field of dentistry, implants, and prosthetics, among others will further enhance the 3D products used for these applications. The shape-changing property of the material used for 4D printing has been one of the major factors influencing the growth of the market.

Moreover, factors such as increasing research and development, rising investment by chemical companies. These chemical companies are keen on grabbing the opportunity for the development of smart materials in 4D printing, which in turn is directly enhancing the growth of the market.

Factors such as stringent regulatory policies for the approval of 4D printing medical devices market and limited skilled professionals have been major challenges for 4D printing in the healthcare market.  

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8630

Market Drivers

• Increasing application of 4D printing in healthcare verticals such as dentistry, implants, and prosthetics.
• The dental industry is one of the major applications of 4D printing. Clear aligners have been the most manufactured products via 3D printing in the dental industry.
• Align technology, the leader in global clear aligners market, accounts for about 80% of the market. The company uses 3D Systems to produce over 1.6 million custom aligners per week.
• Clear aligners can further be enhanced using 4D printing, as these products require shape altering properties according to the changing structure of the teeth on a weekly basis.
• 4D printers are also used to manufacture various dental implants, including dental implants, dentures, crowns, & bridges, among others.
• Increasing prevalence of dental diseases is further influencing the growth of the market. According to the MRFR research study in 2018, it was estimated that oral diseases affected more than 3.7 billion individuals that are around half of the world’s population.

• Rising research and development
• A research team from the US in March 2019, invented a new bio-ink that allows to print catalytically active live cells into several self-sustaining 3D geometries. These properties include tunable cell densities, fine filament thickness, and high catalytic productivity.

• Growing investment by chemical companies
• Various companies such as BASF Venture Capital GmbH and Evonik Venture Capital have invested in Chinese 3D printing companies

Market Challenges

• Stringent regulatory policies for the approval of 4D printing medical devices
• Limited skilled professionals

Segmentation

By Component

• Software & Services: Software and services accounted for the major market share in 2018. 3D printers have already been installed in numerous healthcare facilities across the globe. However, these machines would require updated software and also various services for the manufacturing of 4D products.

• Smart Material: Smart Material segment is expected to grow at the fastest growth rate due to continuous advancements for the materials in 4D printing. Investment by chemical companies for the development of smart material is further influencing the market growth.

By Technology

• Fused Deposition Modeling: Accounted for the largest market share due to its wide choice of raw materials and cost-effective process

• Direct Inkjet Cure: Expected to grow at the fastest growth rate majorly due to its dimensional accuracy, multi-material, and full-color printing properties

By Application

• Dental: accounted for the largest market share owing to the use of 4D printing for manufacturing of wide dental products including clear aligners, implants, and dentures among others

• Prosthetics: Expected to grow at the fastest growth rate due to increasing number of prosthetic procedures, accidental injuries, and sports injuries among others

By End-User

• Hospitals & Surgical Centers: Accounted for the leading market share owing to the increasing number of hospital & surgical centers. According to a study published by the American Hospital Association, there were 5,534 registered hospitals in the US in 2017.

• Dental Clinics & Laboratories (Offices): Use of 4D printing in dental clinics & laboratories, brings less complexity to existing procedures. Dental laboratories use 4D printing technologies that allow them to increase competitiveness and production, thus driving the growth of this segment.

By Region

• Americas: The Americas spearheaded the market in 2018 and is likely to continue to command during the assessment period. This is attributed to the existence of a large number of medical device companies, increasing research and development, and the presence of a large number of noticeable players engaged in manufacturing of 4D printing devices and software

• Europe: Reported for the second-largest share owing to increasing utilization of 3D & 4D printing in the field of healthcare. According to a study conducted in 2018, it was found that 65% of healthcare providers are implementing new printing technologies for medical products using custom made materials

• Asia-Pacific: The highest growth rate is attributed to the growing investment by government bodies and private & public companies. For instance, in November 2018, BASF Venture Capital GmbH invested in Chinese 3D printing company Prismlab.

Key Development

• In January 2019, Dentsply Sirona and Carbon announced a strategic collaboration to revolutionize digital denture materials. This strategic collaboration was announced to deliver denture materials for carbon digital 3D printing production solutions.

Key Players

• Stratasys Ltd (US)
• 3D Systems, Inc (US)
• EnvisionTEC (Germany)
• Poietis
• (France) 
• Organovo Holdings Inc. (US)
• Materialise NV (Belgium)
• Dassault Systèmes (France) Top of Form

Bottom of Form

Browse More Report Details @   https://www.marketresearchfuture.com/reports/4d-printing-healthcare-market-8630 

Meningococcal Vaccines Market 2019 – Leading Manufactures, Regions, Drivers, Analysis And Forecasts Till 2025

Meningococcal Vaccines Market has a demand for USD 172 Million doses in 2019. Further, the global estimated supply in 2019 is expected to be 203 Million doses.

Market Synopsis

Meningococcal meningitis is a bacterial infection caused by Neisseria meningitides. Disease incidence is high in West and Central Africa, where historically, serogroup A has been the most important cause of disease. More recently, meningitis outbreaks have gradually been associated with serogroup C, and to a lesser extent, serogroup W.

The meningococcal vaccines market is complex and diverse, with regional variations in serogroup distribution with substantial use outside routine immunization. The vaccine has approximately 29 marketed products targeting various combinations of the six serogroups (A, B, C, W, X, Y).

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8622

Market Influencer

Without an increase in production, the existing supply of conjugate MenACWY will be inadequate to meet the demand generated by the rising incidence of serogroups C and W, and the low availability of polysaccharide vaccines. Further, several multivalent, conjugate vaccines by Chinese and Indian manufacturers are in the pipeline, and, if prequalified they will be registered for use in many geographies. Moreover, if they are made available at acceptable prices it could increase global demand in Meningococcal Vaccines Market.

Market Drivers

• Rise in prevalence of the meningococcal disease
• According to a document published by the U.S. Department of Health & Human Services, in 2017, there were approximately 350 cases of meningococcal disease reported. The disease has an incidence rate of 0.11 cases per 100,000 people in the United States. Any population group can be affected by the disease, with maximum prevalence in children younger than one-year-old and a second peak in adolescence. Adolescents and young adults, ranging from 16 to 23 years old, have the highest rates of meningococcal disease.
• Further, increasing incidence of meningococcal disease in West and Central Africa regions is expected to drive the demand in the African region
• Booming mortality of the meningococcal disease is leading to increasing demand for the vaccines
• Approximately 10 to 15 in 100 people affected with meningococcal disease will face mortality. Further, up to 1 in 5 survivors will have long-term disabilities, such as loss of limb, deafness, and damage to the nervous system brain among others
• Escalating positive results with the vaccines to boost the demand in the market
• Growing research and development activities by prominent players in the industry

Market Restraints

• Withdrawn production of polysaccharide vaccines has resulted in reduced country access, particularly for MICs in various regions. For example, Sanofi Pasteur, manufacturer of Menomune, declared in 2017 that the company is discontinuing the production of the vaccine. With the production of Menomune at hold, there were no polysaccharide vaccines approved for use in the United States

Meningococcal Vaccines Market Segmentation

By treatment, the market is segmented into Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine.

Meningococcal A conjugate vaccine is significantly used in mass campaigns across affected regions like Africa. Since 2010, the vaccine has significantly decreased meningococcal disease incidence in the region. However, the demand for meningococcal A conjugate in the country remains uncertain given that national immunization program adoptions are based on the timing of Gavi funding decisions, the country’s readiness, and competing for vaccine introduction priorities.

In the polysaccharide segment, products such as MenACWY vaccines are in high demand. MenACWY vaccine is the most desirable combination, given its broader serotype coverage. MenACWY specifically has nine products that are available across polysaccharide and conjugate product segments, but conjugate products are suggested for use in routine immunization activities.

Moreover, the demand and supply of Subcap MenB vaccines is restricted to HICs and influenced by their acceptance into NIPs. Improved uptake of MenB vaccines is expected in the coming years but will likely be moderate and limited to high-income markets given the high price and competing interest of introducing MenACWY conjugate.

By end-user, the market is segmented into Hospital & Clinical, Research Laboratories, and Academic Institutes

Hospitals and clinics control the global market for meningococcal vaccines. The high growth of hospitals and clinics segment is attributed to the increasing application of vaccines in these healthcare facilities in conjunction with the growing prevalence and incidence of the meningococcal disease.

Moreover, research laboratories and academic institutes take up the second-largest share due to the boost in research and development in the market.

By region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

In the global market, China is expected to have the largest market share, which accounts for approximately 35% of the global demand. This is primarily due to polysaccharide products, which currently comprise 84% of China’s demand. Chinese suppliers presently focus only on meeting the demand of the domestic market, but some of the manufacturers have indicated interest in the global market as well. The dynamic product pipeline with several multivalent conjugate products in development may trigger changes in the future supply mix of the Chinese market. Moreover, in China, non-routine use (excluding campaigns) accounts for an estimated 9 million doses in 2019, which may help to sustain the huge market share in the forecast period.

UNICEF foresees all 26 African countries in the meningitis belt, which have completed mass campaigns in 2016. In 2015, seven countries in the region were introduced with meningococcal A conjugate vaccine through their mass campaigns and targeted a population of 233 million. Further, during 2016-2018, UNICEF introduced meningococcal A conjugate vaccine in 26 countries. Ghana was the first country to be introduced with the vaccine into its RI schedule in 2016. Also, four other countries including Mali, Niger, Nigeria, and Sudan introduced the vaccine into RI programs in 2016.

Key Developments in the Global Meningococcal Vaccines Market

• In 2018, Pfizer granted FDA Breakthrough Therapy designation for Trumenba (Meningococcal Group B Vaccine). This vaccine plays a major role in the prevention of invasive meningococcal B disease in children aged 1 to 9 years

• In 2018, GSK’s meningitis B vaccine Bexsero received Breakthrough Therapy designation from the US FDA for prevention of Invasive Meningococcal Disease for children 2-10 years of age

• In 2015, Novartis Bexsero vaccine was approved by the FDA for the prevention of meningitis B. This vaccine is used as active immunization to prevent invasive meningococcal disease caused by serogroup B

Key Players

• Baxter international
• Pfizer Inc.
• Sanofi S.A.
• Novartis Pharmaceuticals Inc.
• JN-International Medical Corporation
• Serum Institute of India Ltd.
• GlaxoSmithKline
• BIO-MED
• Others

Bottom of Form

 Bottom of Form

Bottom of Form

Bottom of Form

Browse more Details of the Report @

https://www.marketresearchfuture.com/reports/meningococcal-vaccines-market-8622

Global Cell Counting Market Outlook, Key Financials, Segmental Revenue And Geographical Revenue Till 2025

Market Forecast

Cell Counting Market is expected to cross USD 12.57 Billion by 2025 at a CAGR of 5.8%.

Market Synopsis

Cell counting is one of the methods for counting cells in life sciences, including medical diagnosis and treatment. The companies operating in this market acquire both organic and inorganic growth strategies to maintain and develop their positions in the market. The increasing funding for stem cell-based research supports the growth of the market.

Market Influencer

Increasing public-private investments and funding in stem cell-based research impact the growth of the cell counting industry positively.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8600

Market Drivers

• The increasing use of stem cells in various therapeutics is promoting government and private institutes to raise the funding for more development in this area. For instance, in March 2019, the governing Board of the California Institute for Regenerative Medicine (CIRM) funded USD 3.9 million to Ankasa Regenerative Therapeutics to develop the treatment for spinal degeneration which can cause chronic, progressive back pain.

• The growth of the market is driven by the increasing number of product launches in the global cell counting devices market. Recently, in January 2019 the DeNovix Inc. launched CellDrop Cell Counting without Slides.

• The cell counting market growth is supported by Increased R&D expenditure in the healthcare industry.

• Increasing number of stem cell organizations globally support the growth of the market.

• Rising incidence & prevalence of cancer will support the growth of the market.

Market Restraints

• The high cost of devices and product recalls are likely to hamper the growth of the cell counting market during the forecast period. Recently in May 2019, Beckman Coulter Inc. recalled DxH800 and DxH600 and DxH 900 hematology analyzers due to risk of inaccurate results.

Cell Counting Market Segmentation

By Product

• Consumables: The consumables segment includes reagents, assay kits, microplates, and others. The instruments are further segmented into reagents, assay kits, microplates, and others. This segment holds the largest share in the cell counting market due to repeating purchase of consumable products.

• Instruments: Instruments are used in cell counting methods. The instruments are further segmented into spectrophotometers, flow cytometers, hematology analyzers, and cell counters. Increasing number of product launches will support the growth of the market. Recently in April 2019, the Nexcelom Bioscience LLC launched Cellaca MX automated cell counter.

By Application

• Research Application: Cell counting is used for research applications for discovering new medicines. Cell counting has the main application in stem cell research to develop advanced therapy for various diseases. This segment holds the largest share in the cell counting market.

• Clinical & Diagnostic Applications: Cell counting has a significant role in clinical and diagnosis applications. It is used for diagnosis of various kinds of blood disorders, including infection, anemia, and leukemia.

• Others: Others include industrial and other commercial applications.

By End-User

• Pharmaceutical & Biotechnology Companies: The largest segment, pharmaceutical, and biotechnology companies, primarily use cell counting for research purposes. In 2018, the pharmaceutical and biotechnology companies segment held the largest share of the market.

• Hospitals: Hospitals used cell counting products for the diagnosis of various kinds of diseases such as blood disorders and malaria, among others.

• Research Institutes: These re involved in specific research activities to develop new and advance treatment for various diseases. Stem cell research institutes are major consumers for cell counting products.

• Others: These include academic institutes, among others.

By Region

• Americas: The Americas dominates the global cell counting market owing to an increase in the incidence of cancer, the presence of well-established pharmaceutical and biotechnology industry, availability of technologically advanced products, and significant support from the government in the form of funds and grants.

• Europe: The key factors driving the market growth are the growing research and development funding and support by government bodies for the healthcare sector, the presence of major manufacturers, and growing healthcare expenditure, among others.

• Asia-Pacific: Asia-Pacific is the fastest-growing region for the cell counting market. This is due to developing healthcare infrastructure and rising drug development researchers.

• Middle East & Africa: It is projected to account for the least share of the global market due to low per capita disposable incomes in the region and limited development of healthcare facilities.

Key Players

• Thermo Fisher Scientific (US)
• Merck KGaA (Germany)
• Danaher Corporation (US)
• Bio-Rad Laboratories, Inc. (US)
• Logos Biosystems, Inc. (South Korea)
• Olympus Corporation (Japan)
• Agilent Technologies, Inc. (US)
• PerkinElmer, Inc. (US)
• Sysmex Corporation (Japan)
• Abbott Laboratories (US)

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cell-counting-market-8600

Medical Drones Market Forecasts By Industry Drivers, Regions Till 2025

Market Forecast

Medical Drones’ Market is expected to worth USD 398 Million by 2025 and is anticipated to register a CAGR of 24.4% during the forecast period (2019 to2025).

Market Synopsis

Medical drones help in the transport of medical supplies such as vaccines, medications, and medical aids. These drones are deployed in remote or inaccessible areas for the rapid & secure distribution of medical supplies and the war-torn regions from medical facilities. Rising public acceptance of medical drone is also driving the growth in medical drones market demand.

Medical Drones Market , In recent years, has been seeking the attention of healthcare providers and governments to offer better healthcare services to remote locations. These drones help in on-time delivery of vaccines, medication, blood, and supplies to the origin and thereby reduce the outbreaks of life-threatening infectious diseases.

How can this technology help in improving safety and care delivery?

• Bedside medication delivery
• Effective treatment from the distance
• Easy reach to an isolated place
• Pre-treatment facility till the time emergency service arrives at takeover

Most of the key players in the market are focusing on developing medical drones to deliver medical supplies to far distances. For instance, in 2016, a Nevada based start-up Flirtey delivered medical test materials and supplies to and from an offshore vessel. This was the first successful ship to shore delivery in the U.S.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8596

Market Influencer

Increasing investments by key players in R&D is the key factor driving the growth of the Global Medical Drones’ Market.

Market Drivers

• Rising participation of Governments in various countries: Active involvement of local governments towards the deployment of drone service to remote and isolated areas is boosting the growth of the market. For instance, in 2018, the government of Ghana has signed an agreement with Zipline (US) for the deployment of drones throughout the country to provide medical supplies to untapped regions

• Increasing application of drone for the supply of medical products such as blood, pharmaceuticals/drugs, and vaccines are anticipated to propel the market growth during the forecast period

• Technological advancements to improving the accuracy of medical drones during emergency cases backed by R&D activities by key players

Market Restraints

• Medical drones. Medical drones are not allowed to fly without the permission of the government. Thus, product approval laws are expected to restrict the growth of the medical drone’s market during the forecast period.

Segmentation

By Application

• Blood Transfer: Rising incidence of severe bleeding deaths is boosting the demand for medical drones. The blood transfer segment is anticipated to show a growth rate of ~24% during the analysis period. According to the MRFR analysis, each year, around 60,000 Americans die from blood loss or hemorrhaging. Moreover, around 2 million people die across the globe.

• Pharmaceutical/Drugs Transfer: The increasing focus of key medical drones vendors towards the development of drones for medication delivery is boosting the growth of this segment.

• Vaccines Transfer: This segment is mainly on the drones that are associated with the delivery of the vaccine.

By End-User

• Emergency Medical Services: This segment held the largest market share in 2018, owing to continues advancements in technology. For instance, in 2019, an automated drone’s delivery company Zipline (US), has planned for the expansion of a medical drone network into Ghana for emergency services.

• Blood Banks: Owing to poor road conditions, transporting blood in underdeveloped countries is a huge task. Medical drones carry blood, plasma, and platelets from blood banks to remote hospitals and clinics.

By Region

• Americas: The Americas held the largest regional market in 2018, owing to rising technology advancement. Moreover, the governments in this region are also promoting the acceptance of medical drones, as a result, players are aggressively working to develop advanced drones. In October 2019, United Parcel Services (US) received an authority from the Federal Aviation Administration to deliver medical packages at hospitals across the country.

• Europe: The European market is expected to be the second-largest market in 2025. The market growth in this region can be attributed to government funding and support to the healthcare sector, coupled with increasing research and development.

• Asia-Pacific: Asia-Pacific is the fastest-growing region for the medical drones market owing to the improving healthcare infrastructure, rising investments in healthcare, and expansions by market players in the region. Also, countries such as India and China are expected to be the fastest-growing in the region due to the focus of governments towards the adoption of new technologies and faster adoption of best treatment options from developed countries.

• Middle East & Africa: It is projected to account for the least share of the global market due to an underdeveloped healthcare sector.

Key Players

• DJI (China)
• DHL (Germany)
• Embention (Spain)
• Flirtey (US)
• Matternet (US)
• Vayu (US)
• Zipline (US)
• EHang (China)
• TUDelft (Netherlands)

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/medical-drones-market-8596 Bottom of Form

Thalassemia Treatment Market Shares Analysis, Key Development Strategies And Forecasts Till 2025

Market Forecast

Thalassemia Treatment Market is expected to cross USD 3763 Million by 2025 at a CAGR of 10.4%.

Thalassemia, specifically the Beta- thalassemia disorder, is majorly caused by the mutation in the Hemoglobin Subunit Beta (HBB) gene. For instance, at least 5.2% of the world population and over 7% of pregnant women have a genetic mutation.

Market Synopsis

Thalassemia Treatment Market analysis asserts that, Thalassemia is an inherited blood disorder wherein the body makes an inadequate amount of hemoglobin. Hemoglobin disorders were initially prevalent in 60% of 229 countries, that potentially affected 75% of births, but are now sufficiently common in 71% of countries amongst 89% of births.

Market Influencers

Major companies are concentrating on mergers and acquisitions, new product developments, approvals, and regional expansions. For instance, in September 2019, Bluebird Bio, Inc. (US) has approved the first gene therapy for Beta-thalassemia. This gene therapy eliminates the need for blood transfusions in patients with β-thalassemia. Thus, major manufacturers are focusing on approvals in thalassemia treatment, which ultimately drives the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8595

Market Drivers

• The rising incidence of thalassemia is expected to drive the growth of the market. Patients with insufficient hemoglobin suffer from thalassemia. For instance, thalassemia affects approximately 4.4 of every 10,000 live births throughout the world.

• Increasing pipeline drugs in thalassemia is expected to drive the growth of the market. There are approximately 15 pipeline products under clinical trials for the treatment of thalassemia. For instance, in December 2016, Kiadis Pharma announced initiation of Phase I/II clinical trial with ATIR201 for thalassemia.

• A rise in awareness regarding available treatment options for the treatment of thalassemia is expected to drive the growth of the market.

• The rise in demand for improved curative gene therapy is expected to drive the growth of the market.

Market Restraints

• Stringent regulatory policies
• High treatment costs

Segmentation

By Type

• Alpha-thalassemia: Fastest growing segment. It is one of the most common autosomal recessive disorders. There is an increased incidence of the alpha-globin disorders in the US and other Western nations which eventually drives the growth of the thalassemia treatment market. However, about 5% of the world’s population is affected by alpha-thalassemia.

• Beta Thalassemia: It is caused by reduced or no production of beta-globin subunits. About 1.5% of the global population is affected by Beta-thalassemia.

By Treatment

• Blood Transfusions: The largest growing segment owing to the low risks involved due to careful blood screening. This treatment gives strong red blood cells along with normal hemoglobin. About 56,000 population have major thalassemia, wherein, at least 30,000 need regular blood transfusions. Thus, rising demand for blood transfusions is expected to drive the growth of the market.

• Iron Chelation Therapy: This includes removing excess iron from the bloodstream. Iron chelator drugs such as desferrioxamine, deferiprone, and deferasirox are majorly used in this treatment.

• Folic Acid Supplements: Folic acid is vitamin B that helps build strong red blood cells. These supplements are majorly consumed during and after pregnancy. However, 4% had started consuming after becoming pregnant. Thus, the increased use of folic acid is expected to drive the growth of this segment.

• Gene therapy: Scientists are investigating genetic techniques to treat thalassemia. Gene therapy named Zynteglo was first launched by Bluebird Bio, Inc. (US) in September 2019.

• Bone Marrow transplants: These transplants are not done very often as significant risks are involved but can be tried if no bone marrow matched donor is available. However, the patient will not need further blood transfusions if this transplantation is done. As a result, it would drive the market growth in this segment.

By End-User

• Hospitals & Clinics: Holds the largest market share owing to the increase in the number of hospital admissions for the treatment of thalassemia. Moreover, increasing occurrence of thalassemia is also expected to drive this segment.

• Diagnostic laboratories: This segment holds significant market share owing to the increasing awareness regarding thalassemia treatment.

• Others: This segment includes research laboratories, educational institutes, among others.

By Region

• Americas: The largest growing regional market owing to rising awareness about thalassemia and increasing government efforts to support gene therapy. However, Beta-thalassemia disorder is relatively rare in the US.

• Europe: The introduction of gene therapy for the treatment of thalassemia is expected to boost the growth of market. For instance, in September 2019, Bluebird Bio, Inc. (US) has obtained approval for gene therapy that would remove the need for blood transfusions for people with blood disorder beta-thalassemia.

• Asia-Pacific: The fastest-growing regional market in thalassemia treatment. Increasing investment in healthcare infrastructure is expected to drive the growth of the market in this region.

• Middle East & Africa: Increasing adoption rate of blood transfusion treatment in countries such as Turkey and GCC would drive the demand for thalassemia treatment in this region.

Key Players

• Novartis AG (Switzerland)
• Bluebird Bio, Inc. (US)
• Kiadis Pharma (Netherlands)
• CELGENE CORPORATION (US)
• Sangamo Therapeutics (US)
• Acceleron Pharma, Inc. (US)
• Gamida Cell (Israel)

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/thalassemia-treatment-market-8595

Worldwide Cardiac Biomarkers Market 2019 Synopsis With Leading Players, Industry Growth Factor Foresight By 2025

Market Forecast

Cardiac Biomarkers Market Size is expected to cross USD 4236.02 Million by 2025 at a CAGR of 16.36%.

Cardiac biomarkers are protein molecules released into the bloodstream from heart muscle damaged by a blocked artery. These enzymes are measured to have an idea of how much muscle damage has been done. These biomarkers are specially used to help diagnosis, evaluate, and monitor patients with suspected acute coronary syndrome (ACS).

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the global Cardiac Biomarkers Diagnostics Market. Out of the 17 million premature deaths due to noncommunicable diseases in 2015, 82% were in low- and middle-income countries, and 37% were caused by cardiovascular diseases.

Market Synopsis

Tests for cardiac biomarkers are used to diagnose acute coronary syndrome (ACS) and cardiac ischemia, conditions associated with insufficient blood flow to the heart. These biomarkers are also helpful in determining a person's risk of these conditions and also helps monitor and manage someone with ACS and cardiac ischemia.

Troponin T and I, CK-MB, and myoglobins are most commonly in the evaluation of acute coronary syndrome. Out of this troponin T and I are the markers of choice for detecting the heart damage. However, other cardiac biomarkers are less specific for heart and may be elevated in other conditions like severe muscle injury, liver disease, and kidney disease.

The increasing incidence of cardiac diseases and related conditions are strongly motivating market players to introduce new efficient technologies in the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8594

Market Influencers

High prevalence of cardiac disorders and increasing participation of market players are actively facilitating the growth of the cardiac biomarkers market. In September 2019, Abbott received FDA clearance for ARCHITECT STAT High Sensitivity Troponin-I blood test. This troponin diagnostic test will be used to detect heart attacks faster and more accurately than contemporary troponin tests.

Market Drivers

• High prevalence of raised blood pressure: Raised blood pressure is the leading risk factor for cardiovascular disease. The prevalence of this troponin T blood pressure in adults aged 18 years and over was around 24.1% in men and 20.1% in women in 2015
• Increasing adoption of outsourcing services
• Growing technological advancements:
• High spending by the pharmaceutical industry
• The increasing popularity of POC cardiac testing kits
• Increasing affordability for advanced cardiac treatments

Market Restraints

• Chances of false diagnosis of myocardial infarction
• High cost of the procedure
• Presence of other efficient methods for the diagnosis of cardiovascular diseases

Cardiac Biomarkers Market Segmentation

By Type

• Myocardial muscle Creatine Kinase (CK-MB): CK-MB has been the gold standard for detecting myocardial necrosis. After myocardial infarction, elevated CK-MB levels appear within 3- 8 hours, peaking within 9-30 hours and levels return to normal after 48- 72 hours

• Troponins (T and I): The most important characteristic of this biomarker is its apparent absolute cardiac specificity. Among patients with acute coronary syndromes, troponins level has been reported to provide prognostic information useful for the early identification of patients with an elevated risk of unstable angina progressing to AMI and death

• Myoglobin: Myoglobin is a low molecular weight heme protein is rapidly released into the circulation and is the first marker to exhibit raising levels after myocardial infarction

• Brain Natriuretic Peptide (BNPs) or NT-proBNP: This biomarker is secreted primarily by the ventricular myocardium in response to wall stress. It is a very useful prognostic indicator in acute coronary syndrome

• Ischemia Modified Albumin (IMA): This novel marker is produced when circulating serum albumin contacts ischemic heart tissues. IMA can be measured by the Albumin Cobalt Binding assay that is based on IMA's ability to bind to cobalt.

By Location of Testing

• Point of Care Testing: Point of care testing expected to witness significant growth in the forecast period due to its increasing popularity

• Laboratory Testing: Laboratory testing segment dominated the global cardiac biomarkers market. Increasing demand for cardiovascular disease diagnostics is boosting the revenue of this segment

By Application

• Acute Coronary Syndrome: This segment holds the largest share owing to the increasing cases of this condition. It is a medical emergency that requires prompt diagnosis and care.

• Congestive Heart Failure: It is a chronic progressive condition that affects the pumping power of your heart muscles

• Myocardial Infarction: Approximately 1.5 million cases of myocardial infarction occur annually in the US region.

• Atherosclerosis: Atherosclerosis is a disease in which plaque builds up inside your arteries. Cardiac troponins are used to assess the prognosis of patients presenting with atherosclerosis

By Region

• Americas: The largest regional market. High prevalence of cardiac diseases is strongly expanding the US cardiac biomarkers market. As per the data suggested by the Centers for Disease Control and Prevention (CDC), around 610,000 people die of heart disease in the US every year. Also, coronary heart disease (CHD) is the most common type of heart disease, killing over 370,000 people annually.

• Europe: Europe has some of the best healthcare services in the world, and rising participation of market players is strongly boosting the Europe cardiac biomarkers market. For instance, in October 2019, Novartis received FDA approval for Entresto for the treatment of symptomatic heart failure in pediatric patients aged one year and older.

• Asia-Pacific: The fastest-growing regional market for Cardiac Biomarkers, Asia-Pacific, has the world’s largest population and fast-developing healthcare industry. Rising affordability for the advanced cardiac treatments and increasing disposable incomes are strongly impacting the growth of the Cardiac Biomarkers market in the region

• Middle East & Africa: The Middle East & Africa has been primarily bifurcated into two regions—the Middle East and Africa. The presence of favorable government initiatives and recent healthcare reforms and developing healthcare infrastructure in the Middle East is expected to augment the market growth over the forecast period.

Key Players

• Abbott Laboratories (US)
• ACS Biomarker (The Netherlands)
• BD (Becton, Dickinson and Company) (US)
• bioMérieux SA (France)
• Bio-Rad Laboratories, Inc. (US)
• Danaher Corporation (US)
• Hoffmann-La Roche Ltd (Switzerland)
• Johnson and Johnson (US)
• Quidel Corporation (US)
• Randox Laboratories Limited (UK)
• Siemens AG (Germany)
• Thermo Fisher Scientific, Inc. (US)
• Trivitron Healthcare Pvt. Ltd. (India)
• Novartis (Switzerland)

Browse More Report Details @   https://www.marketresearchfuture.com/reports/cardiac-biomarkers-market-8594